Mixtures of prion substrains in natural scrapie cases revealed by ovinised murine models by Barrio, T. et al.
1Scientific RepoRtS |         (2020) 10:5042  | https://doi.org/10.1038/s41598-020-61977-1
www.nature.com/scientificreports
Mixtures of prion substrains in 
natural scrapie cases revealed by 
ovinised murine models
tomás Barrio1, Hicham filali1, Alicia otero1, Jessica Sheleby-elías1, Belén Marín1, 
enric Vidal2, Vincent Béringue3, Juan María torres4, Martin Groschup5, olivier Andréoletti6, 
Juan José Badiola1 & Rosa Bolea1*
phenotypic variability in prion diseases, such as scrapie, is associated to the existence of prion strains, 
which are different pathogenic prion protein (PrPSc) conformations with distinct pathobiological 
properties. to faithfully study scrapie strain variability in natural sheep isolates, transgenic mice 
expressing sheep cellular prion protein (PrPc) are used. in this study, we used two of such models to 
bioassay 20 scrapie isolates from the Spain-France-Andorra transboundary territory. Animals were 
intracerebrally inoculated and survival periods, proteinase K-resistant PrP (PrPres) banding patterns, 
lesion profiles and PrPSc distribution were studied. inocula showed a remarkable homogeneity on 
banding patterns, all of them but one showing 19-kDa PrPres. However, a number of isolates caused 
accumulation of 21-kDa PrPres in TgShp XI. A different subgroup of isolates caused long survival periods 
and presence of 21-kDa PrPres in Tg338 mice. It seemed that one major 19-kDa prion isoform and two 
distinct 21-kDa variants coexisted in source inocula, and that they could be separated by bioassay in 
each transgenic model. The reason why each model favours a specific component of the mixture is 
unknown, although prpc expression level may play a role. our results indicate that coinfection with 
more than one substrain is more frequent than infection with a single component.
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are a group of rare, fatal 
and progressive neurodegenerative disorders that affect both animals and human beings. TSEs are caused 
by non-conventional etiologic agents called prions. According to the widely accepted prion hypothesis1, pri-
ons consist exclusively of a pathogenic protein conformer, termed PrPSc, that derives from the physiological, 
host-encoded cellular prion protein (PrPC)1–3 via a post-translational conformational change that is triggered by 
PrPSc itself in a feed-back manner4. PrPSc accumulates in nervous tissue5 and through a yet unclarified mechanism 
gives rise to neuronal death, neuron loss and vacuolization6,7, together with astrogliosis, microgliosis8–10 and other 
neuroinflammatory phenomena11. This progressive degeneration of the central nervous system manifests as a set 
of neurological signs appearing after long incubation periods.
Although, according to the protein-only model1, the agent responsible for these disorders lacks nucleic acids, 
the existence of several phenotypic variants has been proved for different TSEs. This was first described for scra-
pie when two different clinical syndromes were observed in scrapie-infected goats, which were reproducible 
by intracerebral inoculation12. Prion variants associated to these different phenotypes were termed “strains”, by 
analogy with other infectious agents. Further demonstration of the existence of scrapie strains was addressed by 
studies in wild type mice13,14, which also established a methodology to discriminate them according to survival 
periods and lesion profiles15–17.
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Other typing approaches based on the assessment of PrPSc distribution18 or the molecular characterization of 
the prion protein have been successfully employed to discriminate between BSE and scrapie19 and among scrapie 
strains18,20,21.
The existence of prion strains can be accommodated within the protein-only hypothesis through the notion 
that the abnormal conformation of PrPSc is not unique. In this model, prion strains are encoded in the confor-
mation of PrPSc molecules, which can adopt several folding states that are associated to different pathological 
features22–24. Within this framework, the conformational selection model25 proposes that a given amino acid 
sequence for PrPC allows a limited portfolio of conformations, and thus only a number of prion strains will induce 
its misfolding while others will not be able to template its conversion into a disease-associated conformation. As 
a consequence, the degree of overlapping between the Prnp gene sequence of host and donor influences the capa-
bility of an isolate to transmit the disease, which provides a molecular explanation for the transmission barrier 
phenomenon.
The use of wild-type mouse lines expressing different alleles of the murine Prnp gene allowed the differentia-
tion of at least 20 scrapie strains14. However, wild type mice-based typing methodologies may not be reliable since 
many scrapie isolates cannot transmit to these models, including isolates of classical scrapie26,27, unconventional 
scrapie isolates such as CH164128 and atypical scrapie29,30. When transmission to wild-type mice is achieved, 
survival periods tend to be very prolonged and highly variable26. This phenomenon is known as transmission 
barrier31,32 and was also observed in experimental transmissions of other TSEs to rodent models33. Differences in 
PrPC amino acid sequence between donor and host, both on interspecies and intra-species transmission exper-
iments, are frequently acknowledged as the main molecular determinant of transmission barriers, and are also 
responsible for subclinical infections34. Moreover, according to the conformational selection model25, heterotypic 
interaction between PrPSc and PrPC can favour the propagation of PrPSc conformers present in small quanti-
ties25,33, sometimes referred to as “substrains”, and also components or “quasi-species”35. Consequently, studying 
scrapie strain variability by means of bioassay in a model expressing a non-ovine PrPC may alter the original 
portfolio of prion variants to the point that it keeps little if any resemblance with the original sheep scrapie strain 
range.
In this line, the use of homologous murine models, i.e. mice expressing ovine PrPC on a murine Prnp-/-
 background, may be crucial to faithfully recapitulate the actual variability of scrapie prion strains present in 
sheep populations. To this end, several distinct transgenic mouse lines, carrying different alleles (A136R154Q171, 
V136R154Q171) of the ovine Prnp gene, have been created36. These ovinised models show enhanced susceptibility 
to direct sheep scrapie infection37 and have proven useful in studies seeking to characterize field sheep scrapie 
isolates20,21,26,27,38–40. In this study, we used two of such models, the TgShp XI line (expressing ovine ARQ PrPC)41 
and the Tg338 line (expressing ovine VRQ PrPC)42 to study the variability of prion strains and substrains present 
in the tissues of ten naturally scrapie-infected sheep coming from different outbreaks of the disease within the 
Spain-France-Andorra transboundary territory.
Scrapie is present as an enzootic disease in small ruminant populations in most European countries, with 
a prevalence of 7.84 cases per 1000 tested animals in Spain (year 2017)43 and 3.92 cases per 1000 tested ani-
mals in France (2002–2007)44,45. Therefore, its economic and sanitary impact is meaningful. Characterizing and 
holding control of the variety of enzootic scrapie strains present in the small ruminant population through the 
Spain-France-Andorra transboundary territories is crucial for scrapie control and eradication purposes and for 
public health.
Results
Biochemical characterization of nervous and lymphoid tissue sheep scrapie field isolates dis-
closes different biochemical patterns. Ten naturally scrapie-infected sheep were used for this study; six 
of them were at the terminal stage of the disease while four were in a preclinical / early clinical phase. With the 
aim of including as many different scrapie strains as possible, the selection was done according to two criteria: 
(a) animals coming from geographically distant scrapie outbreaks (Supplementary Fig. S1), and (b) animals pre-
senting distinct clinical signs. Clinical stage, clinical signs, genotype, date of sacrifice, age at sacrifice and flock 
of origin of sheep are indicated in Table 1. Both nervous (medulla oblongata) and lymphoid tissues (mesenteric 
lymph node) of sheep were subjected to biochemical analyses prior to bioassay.
Medulla oblongata of sheep #1 to #7 and sheep #9 were positive on Western blot for PrPres and showed a 
banding pattern with the non-glycosylated (NG) bands at around 19 kDa and predominance of diglycosylated 
(DG) species (Fig. 1A). These features resemble those of the experimental isolate CH164146, natural CH1641-like 
isolates from field cases47,48 and other natural sources found in the Spain-France-Andorra transboundary 
territories49.
In contrast, medulla oblongata of sheep #8 and #10 were negative on Western blot (Fig. 1A). Since this is likely 
to be associated with reduced infective titres, they were not used in bioassay.
The presence of PrPres in the lymphoreticular system was demonstrated by Western blot of mesenteric lymph 
nodes from all sheep (Fig. 1B). All but one showed banding patterns with the NG band at around 19 kDa. In 
contrast, inocula 7 L showed a different biochemical profile characterized by a NG band with higher weight 
(~21 kDa), suggesting the presence of a different PrPSc conformer. 21-kDa PrPres banding patterns have been 
commonly observed in the most widely used types of experimental scrapie, including SSBP/1 and Dawson iso-
lates33,46,50,51, and in several natural scrapie cases49.
The presence of different biochemical signatures among our isolates suggests some degree of variability in 
the prion agent they bear. However, to accurately assess the actual range of prion variants present in our inocula, 
the disease phenotype in mice needs to be analysed. For that, sheep tissues were used to prepare nervous (N) 
and lymphoid (L) tissue-derived inocula. Two passages of these inocula were performed in each of the following 
transgenic lines: TgShp XI mice, which express ovine ARQ PrPC with expression levels of between 4 and 8-fold 
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compared to that of sheep brain41, and Tg338 mice, which express ovine VRQ PrPC with expression levels of 
approximately 8-fold those of sheep brain37.
Bioassay in sheep prpc-expressing transgenic mice suggest the presence of more than one 
prion variant. Survival periods and attack rates of first and second-passage TgShp XI and Tg338 mice and 
ID Clinical stage Clinical signs Genotype
Date of sacrifice 
(d/m/y)
Age at 
sacrifice 
(years) Flock of origin Inocula
Sheep #1 Terminal Cachexia, muscle wasting ARQ/ARQ 25/01/2007 5.5 Zaragoza-1
1 N
1 L
Sheep #2 Terminal Cachexia, ataxia, alopecia ARQ/ARQ 03/11/2006 6.5 Zaragoza-2
2 N
2 L
Sheep #3 Terminal Cachexia, ataxia, hyperexcitation ARQ/ARQ 18/08/2008 5 Zaragoza-3
3 N
3 L
Sheep #4 Terminal Cachexia, ataxia, alopecia ARQ/ARQ 21/02/2008 4 Huesca-1
4 N
4 L
Sheep #5 Terminal Apathy, ataxia, teeth grinding ARQ/ARQ 19/12/2007 5.6 Teruel-1
5 N
5 L
Sheep #6 Terminal Cachexia, ataxia ARQ/ARQ 11/06/2008 7 Teruel-2
6 N
6 L
Sheep #7 Early clinical Poor general condition ARQ/ARQ 04/12/2008 3.5 Zaragoza-4
7 N
7 L
Sheep #8 Preclinical No signs ARQ/ARQ 11/11/2008 1.5 Zaragoza-4
–
8 L
Sheep #9 Early clinical Local alopecia ARQ/ARQ 04/12/2008 4.5 Huesca-2
9 N
9 L
Sheep #10 Preclinical No signs ARQ/ARQ 11/11/2008 1 Zaragoza-4
–
10 L
Table 1. Clinical stage, clinical signs, genotype, date and age at sacrifice and flock of origin of sheep included in 
the study, and references of the inocula prepared from their tissues.
Figure 1. Western blot of inocula sourced from sheep tissues. (A) Inocula from medulla oblongata; (B) inocula 
from mesenteric lymph node. Note that all but one samples had banding patterns with the non-glycosylated 
(NG) band at 19 kDa. M: molecular weight marker; kDa: kilodaltons. Notice that cropped images are presented 
here; for the full image, see Supplementary Figure S3.
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banding patterns of second-passage spinal cord pools are presented in Table 2. Banding patterns on first passage 
were coherent with those of second passage.
A majority of brain-derived inocula (1 N, 2 N, 6 N, 7 N and 9 N) produced clinical disease with accumulation 
of 19-kDa PrPres in spinal cord of both TgShp XI and Tg338 mice (Figs. 2A and 3A). Survival periods ranged from 
196 to 381 dpi on first passage and from 183 to 239 dpi on second passage TgShp XI mice. Tg338 mice succumbed 
to disease showing survival periods between 150 and 590 dpi in first passage and 175–200 dpi on second passage. 
Preclinical and early clinical sheep-sourced inocula caused longer survival periods than those sourced from ter-
minal sheep on first passage; however, this difference was reduced on second passage.
Inoculum
Sheep
TgShp XI Tg338
1st passage 2nd passage 1st passage 2nd passage
Banding 
pattern
Survival 
period
Attack 
rate
Survival 
period
Attack 
rate
Banding 
pattern
Survival 
period
Attack 
rate
Survival 
period
Attack 
rate
Banding 
pattern
1 N 19 kDa 196 ± 12 5/5 239 + 56 5/5 19 kDa 150 ± 7 6/6 185 ± 27 6/6 19 kDa
2 N 19 kDa 213 ± 16 6/6 226 + 68 6/6 19 kDa 179 ± 41 5/5 175 ± 29 6/6 19 kDa
3 N 19 kDa 305 ± 62 5/5 312 + 78 5/5 21 kDa 313 ± 110 4/5 199 ± 36 5/5 19 kDa
4 N 19 kDa 273 ± 57 6/6 249 + 50 3/3 21 kDa 327 ± 163 6/6 195 ± 30 6/6 19 kDa
5 N 19 kDa 235 ± 13 6/6 240 + 44 5/5 21 kDa 324 ± 48 5/5 163 ± 5 6/6 19 kDa
6 N 19 kDa 256 ± 57 6/6 202 + 14 5/5 19 kDa 222 ± 82 6/6 200 ± 58 5/5 19 kDa
7 N 19 kDa 346 ± 5 5/5 190 ± 47 4/4 19 kDa 590 ± 58 6/6 189 ± 36 6/6 19 kDa
9 N 19 kDa 381 ± 35 4/4 183 ± 13 6/6 19 kDa 551 ± 48 6/6 188 ± 37 6/6 19 kDa
1 L 19 kDa 455 ± 30 6/6 273 ± 118 12/12 19 kDa 352 ± 22 6/6 231 ± 47 6/6 19 kDa
2 L 19 kDa 454 ± 140 4/4 207 ± 96 5/5 19 kDa 419 ± 45 6/6 646 ± 35 5/6 21 kDa
3 L 19 kDa 425 ± 83 4/4 330 ± 0 4/4 19 kDa 491 ± 69 4/5 249 ± 26 5/5 19 kDa
4 L 19 kDa 443 ± 22 3/3 203 ± 65 6/6 19 kDa 503 ± 77 6/6 490 ± 110 3/6 –
5 L 19 kDa 314 ± 36 5/5 171 ± 20 6/6 19 kDa 528 ± 29 6/6 481 ± 159 3/5 –
6 L 19 kDa 489 ± 80 5/5 276 ± 82 6/6 19 kDa 644 ± 141 5/5 637 ± 4 7/7 21 kDa
7 L 21 kDa 487 ± 38 4/4 241 ± 54 5/5 21 kDa 431 ± 44 4/4 195 ± 31 6/6 19 kDa
8 L 19 kDa 422 ± 90 6/6 175 ± 58 4/4 19 kDa 579 ± 118 4/4 600 ± 40 5/5 21 kDa
9 L 19 kDa 510 ± 63 4/4 163 ± 64 3/3 19 kDa 436 ± 103 6/6 201 ± 46 6/6 19 kDa
10 L 19 kDa 451 ± 78 5/5 321 ± 23 3/3 19 kDa 487 ± 81 4/4 163 ± 7 6/6 19 kDa
Table 2. Banding patterns of source sheep tissues and survival periods, attack rates and banding patterns of 
experimentally challenged first and second-passage TgShp XI and Tg338 mice. Survival period provided as 
mean ± standard deviation (SD).
Figure 2. Western blot of spinal cord homogenates from second-passage TgShp XI mice experimentally 
challenged with (A) sheep brain-derived isolates and (B) sheep lymph node-derived isolates. Note that most 
samples had banding patterns with the non-glycosylated (NG) band at 19 kDa, while those of inocula 3 N, 4 N, 
5 N and 7 L were at 21 kDa. M: molecular weight marker; kDa: kilodaltons. Notice that cropped images are 
presented here; for the full image, see Supplementary Figure S3.
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The rest of brain-derived inocula (3 N, 4 N and 5 N) behaved similarly to the former in Tg338, which showed 
19-kDa banding patterns (Fig. 3A) and survival times between 313 and 327 dpi that shortened to 163–199 dpi on 
second passage, suggesting the propagation of the same prion variant. In TgShp XI, these isolates caused similar 
or subtly longer survival periods in first (235–305 dpi) and second passage (240–312 dpi). However, the biochem-
ical profile in these mice was characterized by an unglycosylated band at 21-kDa (Fig. 2A). This suggests the pres-
ence of minor quantities of a 21-kDa prion conformer, undetectable in the original isolates, that is preferentially 
amplified by the TgShp XI line.
Regarding lymph node-derived inocula, all but one had a single pattern of transmission to TgShp XI mice 
characterized by long survival periods on first passage (314–510 dpi) that shortened to 163–330 dpi on second 
passage, and accumulation of 19-kDa PrPres in their spinal cord (Fig. 2B). In contrast, inoculum 7 L transmitted 
with similar survival periods (241 dpi on second passage) but, alternatively, triggered 21-kDa PrPres deposition in 
mice (Fig. 2B), mirroring that of the original isolate (Fig. 1B). Long survival periods on first passage reflect low 
infectivity titres in lymph node-derived isolates, while on second passage remarkable reductions were observed.
Five of these inocula (1 L, 3 L, 7 L, 9 L and 10 L) transmitted to Tg338 with second-passage survival periods 
ranging from 163 to 249 dpi. Presence of 19-kDa PrPres was noted in spinal cords of both passages (Fig. 3B), even 
in the case of inoculum 7 L. The characteristics of these isolates in Tg338 agreed with those of brain-sourced iso-
lates, suggesting that they contain the same type of agent.
In contrast, the other five isolates (2 L, 4 L, 5 L, 6 L and 8 L) transmitted to Tg338 showing unusual transmis-
sion characteristics. Longer survival periods were observed in first passage (419–644 dpi), which experienced no 
reduction or even considerable lengthening on second passage (481–646 dpi). In a number of occasions, even the 
attack rate was reduced in the second passage, suggesting limited accumulation of infectivity in the spinal cord 
of first-passage animals. Supporting this notion, Tg338 mice from both first and second passages accumulated 
reduced quantities of PrPres in spinal cord as demonstrated by the negative results on Western blot of spinal cord 
homogenates from animals infected with inocula 4 L and 5 L (Fig. 3B). Surprisingly, in the rest of cases (inocula 
2 L, 6 L and 8 L), animals accumulated a PrPres with a 21-kDa banding pattern (Fig. 3B), which provides further 
evidence for the propagation of a different conformer in this mice.
According to transmission patterns and biochemical signatures of the accumulated PrPres, the presence of 
three PrPSc variants can be envisioned: (i) a 19-kDa variant, present as the major component of the majority of 
sheep-sourced inocula, which we termed “19K”; (ii) a 21-kDa conformer that appears as the major isoform in 
inoculum 7 L and as a minor component in other three isolates, and that causes disease in TgShp XI with trans-
mission patterns similar to the 19-kDa variant, hereafter termed “21K-TgShp XI”; and (iii) a 21-kDa conformer, 
different from the former, that seems to block the propagation of the 19-kDa major component exclusively in 
Figure 3. Western blot of spinal cord homogenates from second-passage Tg338 mice experimentally 
challenged with (A) sheep brain-derived isolates and (B) sheep lymph node-derived isolates. Note that 13/18 
samples were clearly positive with non-glycosylated bands at 19 kDa. 5/18 samples differed from this, either 
being negative (4 L and 5 L) or having NG bands at 21 kDa (2 L, 6 L and 8 L). M: molecular weight marker; kDa: 
kilodaltons. Notice that cropped images are presented here; for the full image, see Supplementary Figure S3.
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Tg338 mice, triggering reduced PrPSc accumulation in spinal cord and protracting clinical disease, and termed 
“21K-Tg338”.
Mice brains show distinct histopathological hallmarks. The characteristics of spongiform change 
in both transgenic models were fairly similar. Medulla oblongata, ventral mesencephalon and zona incerta and 
ventrolateral nuclei of diencephalon showed invariably the most severe spongiosis. In sharp contrast, vacuoles in 
cerebellar cortex were usually absent or very scarce. Cortex of superior colliculus and central regions of thalamus 
suffered a milder vacuolization. In hypothalamus, striatum and septal nuclei, the degree of spongiosis was highly 
variable among infected mice groups. Finally, frontal and temporo-parietal cortices and hippocampal formation 
were poorly affected.
Lesion profiles were drawn for each inoculum and murine line. In most cases, curves fitted to a general profile 
characterized by high scores at brainstem and subcortical structures, moderate scores in cerebral cortices and 
hippocampus, and low scores in cerebellar cortex. However, a number of isolates triggered lesion profiles with 
significantly lower vacuolization severity in all areas.
Both 19K substrain (Fig. 4A) and 21K-TgShp XI substrain-containing inocula (Fig. 4B) caused in TgShp XI 
mice similarly shaped lesion profiles (Fig. 4C), most of them characterized by peaks at medulla oblongata, mes-
encephalon and thalamus.
In contrast, inocula bearing the 19K substrain (Fig. 5A) and the 21K-Tg338 substrain (Fig. 5B) showed differ-
ences in the lesion profiles they triggered in Tg338 mice. The later were characterized by flatter curves, with less 
evident peaks, and that, on average, were lower than those caused by the other group of isolates (Fig. 5C). This 
finding reinforces the idea that these inocula contain a different type of prion.
PrPSc distribution was assessed using PET-blot. TgShp XI mice showed in general lower staining intensity in 
comparison with Tg338 mice. Two trends of PrPSc deposition could be differentiated. The first was a generalized, 
widespread low-intensity immunostaining (Fig. 6A,B,C), which correlated with synaptic deposits in IHC and 
was more intense in medulla oblongata, deep cerebellar nuclei, mesencephalon, medial and lateral nuclei and 
zona incerta of thalamus, hypothalamus and septal area. The second pattern consisted of localized high-intensity, 
plaque-like deposits, which were found frequently associated to the alveus of hippocampus (Fig. 6B,D) and sub-
ependymal areas at the level of 3rd and 4th ventricles (Fig. 6D), and correlated with coarse particulate/coalescing 
deposits in IHC (Fig. 6E).
PrPSc deposits in the brains of Tg338 mice were mostly of the generalized or synaptic type. The distribution 
pattern was characterized by high staining intensities of brainstem and subcortical areas. Medulla oblongata and 
deep cerebellar nuclei, mesencephalon, medial and dorsal nuclei of thalamus and zona incerta, and hypothalamus 
were the most affected zones (Fig. 7). A correlation between the distribution of spongiform lesions and PrPSc 
deposits was observed in both TgShp XI and Tg338 mice, as seen by the overlapping of the curves and by the 
positive and statistically significant Spearman’s correlation coefficients (Supplementary Fig. S2).
In addition, mild to intense staining was observed in specific structures, including the cingulate gyrus 
(Fig. 7A,B,E), the habenular nuclei (Fig. 7A,C), and the stratum lacunosum-moleculare and the alveus of hip-
pocampus (Fig. 7B,E). Finally, intense immunostaining of medial amygdaloid nuclei (Fig. 7D,E) was observed 
exclusively in Tg338 inoculated with isolates 6 L and 8 L, which were associated to long survival periods and low 
average spongiosis.
These same inocula (6 L and 8 L) led to the formation of amyloid plaques in the brain of second-passage 
Tg338 mice. These plaques were visible on PET-blot as granular plaque-like depositions at the level of thala-
mus and mesencephalon (Fig. 7D,E), and in haematoxylin and eosin (H&E)-stained slides (Fig. 8A,D,G,J). They 
were congophilic, which demonstrate their amyloid nature (Fig. 8C,F,I,L), and positive to immunohistochemistry 
with anti-PrP antibody SAF84 (Fig. 8B,E,H,K). Plaques were usually multicentric or amorphous and were found 
mostly in a perivascular location and lying beneath the pia mater of frontal, parietal and piriform cortices and 
cortex of the superior colliculus. In a number of animals, unicentric and occasionally florid plaques were found in 
the deep layers of medulla oblongata, mesencephalon, hypothalamus and thalamus. Interestingly, this phenotypic 
feature was not observed in TgShp XI mice.
Discussion
There is a wide basis of evidence that the characterization of scrapie strains based on data recorded directly from 
the ovine host is a difficult task52,53. Differences in clinical signs of sheep or in lesion profiles and distribution of 
PrPSc deposits in their brains may not reflect the presence of different strains, since several uncontrolled factors 
are known to contribute to this heterogeneity, including age of infection, breed, intercurrent diseases and effects 
of currently unidentified genes. This problem has been routinely circumvented by bioassaying the isolates in 
genetically stable rodent models. The advent of transgenic murine lines expressing homologous PrPC has allowed 
shedding light on the actual variability of scrapie prion strains, avoiding confounding effects exerted by strain 
selection/mutation phenomena in wild-type mice20,26,38–40,54.
In our experiment, sheep brains showed a remarkable homogeneity in banding patterns, all of them possess-
ing non-glycosylated (NG) bands with molecular weights of around 19 kDa and a predominance of the digly-
cosylated (DG) species. This biochemical signature has been linked to the CH1641 isolates, but also to other 
unconventional isolates found in the field47–49. On the other hand, PrPres in isolates prepared from mesenteric 
lymph nodes reproduced the same pattern in almost all cases; the only exception was isolate 7 L, whose NG band 
had a molecular weight of 21 kDa.
Concerning transmission properties, most isolates showed survival periods always shorter than 330 dpi on 
second passage. In contrast, a number of inocula (2 L, 4 L, 5 L, 6 L and 8 L) triggered very protracted survival peri-
ods (longer than 481 dpi) and absence of evident reductions on second passage in the Tg388 line. Regardless of 
whether this difference was caused by reduced accumulation of infectivity in spinal cord of first-passage mice or 
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because they have intrinsically longer survival periods, it suggests the existence of a different strain in this group 
of samples.
Regarding banding patterns, non-equivalent results were found between TgShp XI and Tg338 lines. TgShp 
XI mice accumulated high (21-kDa) PrPres in spinal cord after the inoculation of isolates 3 N, 4 N, 5 N and 7 L, 
although only one of these (inoculum 7 L) displayed this high-molecular weight banding pattern. The prion var-
iant propagated in these cases has been termed “21K-TgShp XI” and did not correlate with other differential 
phenotypic features such as lesion profiles, vacuolization scores, or PrPSc distribution patterns.
Another group of isolates (2 L, 4 L, 5 L, 6 L and 8 L) triggered no accumulation or accumulation of a 21-kDa 
isoform exclusively in Tg338 mice. Notably, these same isolates caused long survival periods, milder spongiosis, 
flatter lesion profiles, characteristic immunostaining of lateral amygdaloid nuclei and, in a number of cases, pres-
ence of PrP amyloid plaques in Tg338 mice. The combination of these differential features allows proposing that a 
distinct prion conformer, here referred to as “21K-Tg338”, has been propagated in these cases. Upon comparison 
with other studies, the behaviour of this prion variant resembled that of the scrapie source that caused several 
outbreaks in Italy in the 90 s following an iatrogenic infection with a vaccine against Mycoplasma agalactiae55–58, 
Figure 4. Lesion profiles of second-passage TgShp XI mice. Both inocula associated to the 19K phenotype (A) 
and inocula associated to the 21K-TgShp XI phenotype (B) provoked similarly shaped lesion profiles in TgShp 
XI mice (C), most of them characterized by peak scores at mesencephalon and thalamus. The brains of all mice 
dying after the onset of clinical signs in each challenged group were analyzed to plot lesions profiles (usually 6 
and never less than 3 animals per group). Mobl: medulla oblongata, Cb: cerebellar cortex, Mes: mesencephalon, 
Hy: hypothalamus, Th: thalamus, Hp: hippocampus, Sn: septal nuclei, Tc: cortex at the level of thalamus, Fc: 
frontal cortex. Error bars represent SEM.
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including the accumulation of PrP plaques with a distribution similar to what we observed58. In other study, an 
isolate coded MF17, whose properties resemble those of Italian scrapie (O. Andréoletti, unpublished observa-
tions), demonstrated zoonotic potential as it was able to infect transgenic mice expressing human PrPC43. Studies 
are underway to determine if the coincidence of phenotypic traits is enough to endorse our inocula with zoonotic 
capability.
In the rest of cases, a 19-kDa conformer, likely corresponding to the one predominating in most of the origi-
nal sheep isolates, was propagated and termed “19K”. Importantly, both murine lines were able to propagate this 
conformer. The phenotype associated to this form of the agent resembled that of CH1641-like isolates46,47,59,60. 
CH1641 scrapie is associated with a PrPres banding pattern with low (19–20 kDa) NG species and possesses dis-
tinctive biological properties. In natural cases, it causes longer incubation periods in sheep with the s7 allele of 
the Sip (Prnp) gene and shorter in sheep with the p7 allele, contrary to the more common scrapie sources studied, 
including SSBP/128. Contrary to other classical scrapie sources, the original, prototypic CH1641 source does not 
transmit to wild type mice28. However, it does transmit without apparent difficulties to transgenic mice expressing 
ovine PrPC, which replicate the PrPres banding pattern of the source inocula47, in agreement with our own results. 
Figure 5. Lesion profiles of second-passage Tg338 mice. Inocula associated to the 19K phenotype provoked 
similar lesion profiles in Tg338 mice, mostly characterized by peaks at medulla oblongata and thalamus (A). 
However, isolates linked to the 21K-Tg338 phenotype triggered lower and flatter profiles (B,C). The brains of 
all mice dying after the onset of clinical signs in each challenged group were analyzed to plot lesions profiles 
(usually 6 and never less than 3 animals per group). Mobl: medulla oblongata, Cb: cerebellar cortex, Mes: 
mesencephalon, Hy: hypothalamus, Th: thalamus, Hp: hippocampus, Sn: septal nuclei, Tc: cortex at the level of 
thalamus, Fc: frontal cortex. Error bars represent SEM.
9Scientific RepoRtS |         (2020) 10:5042  | https://doi.org/10.1038/s41598-020-61977-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Due to its biochemical features, these isolates were suspected to contain BSE infectivity46, although this was later 
discarded. To date, this type of scrapie has not been attributed a zoonotic potential49 (O. Andréoletti, unpublished 
observations).
All studied isolates seemed to contain the “19K” component, since in all cases at least one of the transgenic 
lines reproduced the phenotype associated to this isoform. However, TgShp XI propagated the “21K-TgShp XI” 
component when a number of brain-derived isolates and one lymph node-derived isolate were used. The fact that 
not all isolates induced the propagation of this variant indicates that the “21K-TgShp XI” component pre-existed 
in these inocula and was not generated de novo. The reason why Tg338 mice were unresponsive to the presence of 
“21K-TgShp XI” prions and manifested solely the phenotype associated to the major “19 K” component remains 
unresolved. The possibilities are that it is caused by the PrPC amino acid mismatch between sheep (ARQ PrPC) 
and Tg338 mice (VRQ PrPC) or by differences in PrPC expression levels, as recently proposed61, and discussed 
below.
In contrast, half of the lymph node-derived inocula provoked in Tg338 mice a characteristic phenotype that 
was associated with the propagation of the “21K-Tg338” isoform, which probably pre-existed in these inocula as 
a minor component. This conformer is somehow able to intercept the propagation of the major “19K” component 
exclusively in Tg338 mice, strongly protracting survival periods and triggering less severe neuropathology. This 
interception may be mediated by the formation of PrP amyloid plaques, as observed in previous studies with 
the Italian isolate58 and in this study for inocula 6 L and 8 L. According to some authors, amyloidogenesis may 
Figure 6. PrPSc distribution in representative brain sections from TgShp XI mice infected with inocula 2 N 
(A), 3 N (B), 7 L (C) and 8 L (D). Two different trends of PrPSc accumulation were observed on PET-blots: a 
generalized low-intensity immunostaining (A,B,C), and a localized high-intensity pattern, usually associated 
with the alveus of hippocampus (B, D, arrowheads), and subependymal areas (D, arrowheads), and which 
correlated with coarse/coalescing plaque-like deposits on immunostochemistry (E).
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comprise a defensive system by means of which toxic small PrP oligomers25,34,62 are sequestered into bigger struc-
tures, thus delaying or restraining the neurotoxicity caused by prion progression63–65.
Although the conclusion is that there is an intrinsic variability of prion agents in natural scrapie cases that can 
be resolved by means of bioassay, the mechanisms though which each transgenic murine line selectively propa-
gates distinct conformers are far from clear. In this line, a recent study has described how high-level expression 
of ovine PrPC favours the selection of minor components in a mixture of prion quasi-species, and moreover, 
triggers the de novo generation of new, favoured conformers61. Whether such a mechanism may participate in 
the divergence observed in our study needs to be evaluated. A possibility is that the ability of each transgenic line 
to amplify distinct prion conformers is due to their different rates of PrPC expression (4–8-fold vs. 8-fold), rather 
than, or in combination with, differences in the sequence of the PrPC they bear.
Interestingly, the “21K-Tg338” component was only found in lymphoid tissues from sheep. It is widely 
accepted that, upon natural, oral infection in sheep, prions invade the gut-associated lymphoid tissue and pro-
gressively extend to the rest of the lymphoreticular system (LRS)66,67. During this process, the LRS may favour the 
propagation of specific prion conformers, different from the isoforms that later invade the nervous system. This 
phenomenon has been observed in ovinised mice whose brain and spleen accumulated PrPSc with differential 
banding patterns and biological properties68. This situation is reminiscent of the case of humanised transgenic 
mice inoculated with variant CJD (vCJD) prions that developed a disease phenotype compatible with sporadic 
CJD (sCJD), but still accumulated vCJD PrPSc in their spleens69.
Figure 7. PrPSc distribution in representative brain sections from Tg338 mice infected with inocula 1 L (A), 3 L 
(B), 7 L (C) and 8 L (D,E). A general pattern arose in all examined brain samples consisting of intense staining of 
brainstem and subcortical areas. Additionally, conspicuous immunostaining was observed in specific structures, 
including the cingulate gyrus (A,B,E; thick orange arrows), habenular nuclei (A,C; red arrowheads), and the 
stratum lacunosum-moleculare and the alveus of hippocampus (B,E; thin green arrows). High-intensity staining 
of the medial amygdaloid nuclei (D,E; blue triangles) was observed in a subset of samples obtained from 
animals challenged with isolates causing prolonged survival periods and low vacuolization scores.
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Nevertheless, the reasons why brain and lymphoid organs propagate distinct prion conformers have not been 
clarified. It has been proposed that differences in the glycosylation of the PrPC between these two tissues may be 
involved in the selection of PrPSc isoforms with specific glycoform ratios70. In addition, the aforementioned study 
by Le Dur et al. suggests an alternative mechanism based on differences in PrPC expression level61.
In any case, our results indicate that in natural scrapie cases, sheep can be infected with more than one strain. 
These distinct variants of the agent can be present in different organs (we assessed nervous and lymphoid tissues), 
or even coexist in the nervous system as prion mixtures with a dominant conformer and one or more subdomi-
nant isoforms, which can be detected by bioassay in sensitive rodent models or other in vitro techniques. In fact, 
according to our results, the coinfection seems to be more frequent that the infection with a single strain.
The notion that natural scrapie cases may be caused by mixtures of substrains is not new. There are many 
precedents in the literature: (i) when a methodology that separate short and long-incubation period strains was 
employed, natural scrapie isolates were found to contain a mixture of strains that could be isolated in different 
lines of wild type mice54. (ii) When several wild-type and transgenic lines were used in a bioassay to investigate 
a number of scrapie isolates suspected to contain BSE infectivity, different results with lines TgShp XI and Tg338 
were obtained, which suggest that different strains existed in the isolates that each mouse line propagated selec-
tively71. (iii) When CH1641-like scrapie isolates were inoculated in wild-type mice, transmission was achieved 
in disagreement with previous reports, although glycosylation profiles and histopathological features changed. 
These results were compatible with a selection of a minor component that was able to replicate in wild-type mice, 
in contrast with the CH1641 experimental isolate72. (iv) Other authors73 also worked with CH1641-like isolates 
and found them to be comprised of an ensemble of different conformers than could be differentiated by the use of 
Western blot and separately propagated in distinct sheep breeds and murine lines. All these results are in agree-
ment with ours and drag the risk of sheep getting infected with multiple scrapie strains into the spotlight.
This situation is somehow similar to some cases of sporadic CJD (sCJD) in humans, which were shown to pos-
sess a mixture of high and low-molecular weight conformers in their brains or in different parts of their brains74. 
Figure 8. Unicentric (A to C), florid (D to F) and amorphous perivascular plaques (G to L) in brain of 
second-passage Tg338 mice infected with inocula 6 L and 8 L. Haematoxilin-eosin staining (A,D,G,J), 
immunohistochemistry with anti-PrP mAb SAF84 (B,E,H,K) and Congo red staining that proves the amyloid 
nature of the plaques (C,F,I,L).
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Even in variant CJD (vCJD) cases, 21-kDa PrPSc conformers have been occasionally found75, which raises doubts 
about the current classification of human prion strains and the actual responsible of each type of clinical profile.
Characterization and monitoring of prion strains in small ruminant populations in Europe is crucial for con-
trol and eradication purposes. Shedding light on the actual variability of scrapie prions and its implications for 
inter-species transmission and, particularly, on the zoonotic potential of scrapie field isolates is necessary to 
update communitarian public health policies and to prevent a putative reemergence of prion diseases as a public 
hazard.
Methods
Sheep. The diagnosis of scrapie in terminally-affected sheep was stablished using standardized clinical exam-
ination. In contrast, preclinical and early clinical animals were identified in vivo thought rectal biopsy and immu-
nohistochemical detection of PrPSc on rectal mucosa-associated lymphoid tissue using monoclonal anti-PrP 
antibody L42 (R-Biopharm), as described elsewhere76.
Animals were sacrificed by intravenous injection of sodium pentobarbital followed by necropsy and system-
atic sampling. Samples from brain and mesenteric lymph nodes were divided into two halves; one half was fixed 
in a solution of 10% formalin for further histological studies, while the other was immediately immerged in liquid 
nitrogen and later conserved at −80 °C for biochemical analyses and the preparation of inocula.
After sacrifice, the presence of PrPSc was confirmed for both the terminal and the preclinical/early clinical 
group in both nervous and lymphoid tissues using immunohistochemistry with monoclonal anti-PrP antibody 
L42 (R-Biopharm), whose epitope spans amino acids 145–163 of ovine PrP. Additionally, the Prnp genotype was 
determined through sequencing of genomic DNA obtained from whole blood samples.
inocula. First-passage inocula were prepared from nervous (N) and lymphoid tissues (L) of the aforemen-
tioned sheep. Inocula 1 N to 10 N corresponded to inocula prepared from medulla oblongata (obex), while inoc-
ula 1 L to 10 L were those prepared from mesenteric lymph nodes of the animals. Inocula 1 N to 6 N and 1 L to 
6 L derived from tissues of terminal sheep, while inocula 7 N to 10 N and 7 L to 10 L sourced from preclinical / 
early clinical sheep. Second-passage inocula were prepared from pools of spinal cords harvested from diseased 
first-passage mice. All inocula consisted of 10% (w/v) tissue homogenates in physiological saline and were sub-
jected to microbiological analysis to ensure sterility prior to intracerebral inoculation.
Mice. TgShp XI mice express ovine ARQ PrPC with expression levels of between 4 and 8-fold compared to that 
of sheep brain41. These animals were kindly provided by M. Groschup (Friedrich-Loeffler-Institut, Greifswald - 
Insel Riems, Germany) and were brought to our facilities to be inoculated after the appropriate adaptation period.
The transgenic murine line Tg338 was developed by H. Laude and J.L. Vilotte (INRA, Jouy-en-Josas, France)42 
and is homozygous for the ovine Prnp gene, VRQ allele, expressing ovine VRQ PrPC under the control of the 
ovine PrP promoter37. The level of expression of this line is approximately 8-fold that of sheep brain. This line 
was provided by O. Andréoletti (ENVT-INRA, Toulouse, France) and was maintained and bred in our facilities.
All experimental procedures in this study were approved by the Ethics Committee for Animal Testing of the 
University of Zaragoza (permit number PI19/14) and performed in accordance with the recommendations for the 
care and use of experimental animals and in agreement with Spanish law (RD 1201/05).
intracerebral inoculation. A dose of 20 µl/animal of each inoculum was administered by the intracerebral 
route to groups of six mice using a precision syringe and under general anaesthesia. Animals were provided 
adequate analgesia after the procedure, consisting of buprenorphine at a dose of 0.01 mg/kg bodyweight by the 
subcutaneous route, and were caged together.
Bioassay. Animals were monitored three times per week for clinical signs of prion disease. When the end 
point criteria were met, animals were sacrificed by cervical dislocation under heavy anaesthesia. Brain and spinal 
cord were harvested and stored in a 10% formalin solution and at −80 °C for histopathological and biochemical 
analyses, respectively.
Western blotting. Western blotting was performed following a protocol based on TeSeE Western Blot kit 
(Bio-Rad). Briefly, medulla oblongata and mesenteric lymph node samples from sheep and spinal cord pools 
from diseased mice were thawed and homogenised in a detergent-containing solution. A volume of 200 µl was 
submitted to proteinase K digestion for 10 min, which was stopped using a β-mercaptoethanol-containing stop 
buffer, followed by concentration, clarification and resuspension of the remaining PrPres in 30 µl of Laemli loading 
buffer. It was then subjected to SDS-PAGE electrophoresis using commercial 12% Bis-Tris gels (Bio-Rad), fol-
lowed by transference to a PVDF membrane with 0.20-µm pore diameter (Bio-Rad). Immunoblot was performed 
by sequentially immerging the membrane in a blocking solution (0.2% BSA in PBS+Tween 0.1%), primary 
anti-PrP antibody Sha31 (whose epitope spans amino acids 148–155) diluted 1:8,000 in PBS+Tween 0.1%, and 
HRP-conjugated secondary antibody diluted 1:5,000 in PBS+Tween 0.1%. Finally, membranes were developed by 
incubation with a luminol-based substrate (SuperSignal West Pico Chemiluminescent Substrate).
tissue processing. Brain and lymph node samples from sheep and brains from diseased mice were fixed in 
a 10% formalin solution for at least 48 hours before being processed. Mouse brains were trimmed in four sections 
following Fraser and Dickinson’s protocol15, while sheep tissues were processed as usual18. Tissues were then 
embedded in paraffin wax and mounted in histological cassettes. Four µm-thick sections were obtained using a 
microtome and mounted on glass slides for subsequent histological procedures.
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Haematoxylin and eosin staining. Haematoxylin and eosin (H&E) staining of the sections was per-
formed following a standard protocol. Briefly, dewaxing and rehydration was performed by sequentially pas-
saging the preparations in xylene and graded alcohols, followed by incubation in a haematoxylin solution. After 
rinsing with tap water, preparations were subjected to incubation in acid alcohol (1% acetic acid in a 70% ethanol 
solution), followed by immersion in an eosin solution. Finally, preparations were dehydrated and mounted prior 
to visualization under light microscope.
immunohistochemistry. Immunohistochemistry was applied to brain and lymph node samples from 
sheep and brain sections from mice. After dewaxing and rehydration, three different pre-treatments for antigen 
retrieval were performed sequentially: immersion in 98% formic acid for 15 min, treatment with 4 µg/ml pro-
teinase K for 15 min at 37 °C, and hydrated autoclaving in citrate buffer at 96 °C for 20 min. Following antigen 
retrieval, endogen peroxidase activity was blocked using a commercial blocking solution, followed by 1-hour 
incubation with primary anti-PrP antibody L42 (1:500, R.Biopharm) for sheep tissues or 6H4 (epitope aa 147–
155, 1:100, Prionics) and SAF84 (epitope aa 160–170, 1:1,000, SPI-Bio) for mice brains. The EnVision+ System 
(Agilent Dako) was used as the secondary antibody, and the DAB + System (Agilent Dako), based on the use of 
3,3’-diaminobenzidine (DAB) as chromogen, was employed for development.
Paraffin-embedded tissue-blot (PET-blot). PET-blot was performed as described elsewhere77 on mice 
brain samples. Briefly, 4-µm paraffin-embedded brain sections were collected onto a nitrocellulose membrane 
and dried at 37 °C for 24 hours. Membranes were then subjected to dewaxing and rehydration and incubated for 
2 hours in a solution of proteinase K (250 µg/ml) at 56 °C to completely digest PrPC. Denaturation of the remain-
ing PrPres was achieved by incubating the membranes in a solution of guanidine thiocyanate 3 M. After blocking 
the membrane with 0.2% BSA to avoid cross-reactivity, detection was carried out through sequential incubation 
with the anti-PrP antibody Sha31 (1:8,000, SPI-Bio) and a secondary alkaline phosphatase (AP)-conjugated anti-
body (1:500, Agilent Dako), followed by development with NBT/BCIP (Thermo Scientific). Membranes were 
then washed and dried for 24 hours at room temperature.
Lesion and prpSc distribution profiling. H&E-stained and PET-blotted brain samples from 
second-passage animals were inspected and spongiosis and PrPSc accumulation were was measured in nine 
pre-determined grey matter areas following a standardized protocol15. The areas were: (1) dorsal nuclei of medulla 
oblongata, (2) cerebellar cortex, (3) superior colliculus of the mesencephalon, (4) hypothalamus, (5) thalamus, 
(6) hippocampus, (7) lateral septal nuclei, (8) cerebral cortex at the level of the thalamus and (9) frontal cortex. 
Semiquantitative scores from 0 (absence of vacuolization or PrPSc accumulation) to 5 (very abundant and conflu-
ent vacuoles or PrPSc deposits) were given to each area. Mean values at each area were plotted to trace the curves 
for each inoculum. Visual comparison was performed between curves corresponding to each inocula, as well 
as between lesion profiles and or PrPSc distribution curves. In addition, the statistical correlation between both 
parameters was computed through the Spearman’s correlation coefficient for each transgenic line. The software 
used was GraphPad Prism 5.
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